Structure Therapeutics Inc. (NASDAQ:GPCR) showcased preclinical findings for ACCG-2671 and GSBR-5595 in two late-breaking posters at the ADA 85th Scientific Sessions.

What a data analyst does. Key data-driven equipment metrics. How data benefits maintenance management. How to manage expectations when implementing change. William A. Hazel runs a mixed fleet and ...

Recursion Deprioritizes 3 Clinical Programs Following Data-Driven Review, Stock Down May 05, 2025 — 08:46 am EDT Written by RTTNews.com for RTTNews -> ...

Recursion will present preliminary safety and efficacy data for REC-4881 in familial adenomatous polyposis at DDW 2025.

A young computer scientist and two colleagues show that searches within data structures called hash tables can be much faster than previously deemed possible.

Recursion Announces Promising Clinical Data on Lead AI-Based Drug Candidate for Brain Disease Cerebral cavernous malformation (CCM) patients treated with oral drug, REC-994, showed reduction in ...

JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.

Abstract: The paper describes recent improvements made to the structural recursion of the Data Funnel Interface. This end user interface organizes the raw data in a database table into a series of ...

Recursion Pharmaceuticals (RXRX) stock slips as company announces topline results from a Phase 2 trial for REC-994 in cerebral cavernous malformation. Read more here.